<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap15" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>15</ChapterID>
          <ChapterNumber>Chapter 15</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_15</ChapterDOI>
          <ChapterSequenceNumber>15</ChapterSequenceNumber>
          <ChapterTitle Language="En">Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>163</ChapterFirstPage>
          <ChapterLastPage>177</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Tristan</GivenName>
                <GivenName>M.</GivenName>
                <FamilyName>Sissung</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_15" CorrespondingAffiliationID="Aff1_15">
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <GivenName>D.</GivenName>
                <FamilyName>Figg</FamilyName>
              </AuthorName>
              <Contact>
                <Email>wdfigg@helix.nih.gov</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_15">
              <OrgDivision>Medical Oncology Branch, Center for Cancer Research National Cancer Institute</OrgDivision>
              <OrgName>National Institute of Health</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_15" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Cytotoxic chemotherapy using docetaxel, estramustine, and mitoxantrone is often employed to treat men with hormone-refractory prostate tumors. More recently, oral satraplatin has been studied as an alternative to docetaxel-based therapies. These cytotoxic agents have diverse mechanisms of action and disposition. Moreover, there is often wide interindividual variation in the pharmacokinetics, toxicity, and clinical outcome following administration of these agents in patients with prostate cancer. This chapter summarizes what is known about the basic clinical pharmacology of these agents and discusses the mechanisms and implications of interindividual variation in treatment.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Docetaxel</Keyword>
            <Keyword>Mitoxantrone</Keyword>
            <Keyword>Estramustine</Keyword>
            <Keyword>Satraplatin</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Pharmacogenetics</Keyword>
            <Keyword>Pharmacology</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">In 2008, the National Cancer Institute documented 186,320 new cases and 28,660 deaths due to prostate cancer. The majority of deaths are expected to have occurred in men with metastatic castration-resistant prostate cancer (CRPC), and a large proportion of these men likely received cytotoxic chemotherapy prior to death. However, CRPC has only been effectively treated with cytotoxic agents as recently as 2004 with the approval of docetaxel as the standard of care in metastatic CRPC. Docetaxel-based therapy still only provides an approximate 2–3-month survival benefit over palliative care with mitoxantrone plus prednisone [<CitationRef CitationID="CR1_15">1</CitationRef>, <CitationRef CitationID="CR2_15">2</CitationRef>]. Other chemotherapies, such as oral satraplatin, have been introduced in men with CRPC with limited success.</Para>
            <Para TextBreak="No">There is often great interindividual variation in the survival and palliative benefits of these chemotherapies despite their often-narrow therapeutic indices. Thus, treatment is more or less effective or toxic within certain subgroups based on differences in genetic, morphometric, physiological, and demographic parameters. Furthermore, there are notable differences in pharmacokinetics (PK) brought on by interindividual variation suggesting that individualized dosing could improve therapeutic outcome in some cases. The purpose of this chapter is to summarize what is currently known about the mechanism, clinical pharmacology, interindividual variability, and pharmacogenetics of the major cytotoxic agents that have been used in prostate cancer including docetaxel, estramustine, mitoxantrone, and satraplatin.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Docetaxel</Heading>
            <Section2 ID="Sec3">
              <Heading>Mechanism of Action</Heading>
              <Para TextBreak="No">Docetaxel binds to β-tubulin and promotes the polymerization of microtubules while also inhibiting depolymerization. This disrupts the normal dynamics of microtubules that are required for formation of the cytoskeleton and the movement of the mitotic spindle, ultimately leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. Docetaxel has other proapoptotic effects as well including inhibiting the antiapoptotic protein BCL2 overexpression, interactions with BCLxl, upregulation of p53, and antiangiogenic properties [<CitationRef CitationID="CR3_15">3</CitationRef>, <CitationRef CitationID="CR4_15">4</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Pharmacokinetics, Drug Distribution, and Pharmacodynamic Determinants</Heading>
              <Para TextBreak="No">Docetaxel can be assayed in plasma with a detection range of 5–1,000 ng/mL by high performance liquid chromatography-mass spectrometry (HPLC-MS) [<CitationRef CitationID="CR5_15">5</CitationRef>–<CitationRef CitationID="CR7_15">7</CitationRef>]. Other methods have been developed to determine unbound docetaxel levels [<CitationRef CitationID="CR8_15">8</CitationRef>] as well as the concentration of its vehicle, polysorbate 80 [<CitationRef CitationID="CR9_15">9</CitationRef>], allowing for sophisticated PK determinations. Docetaxel is administered intravenously, and the distribution is generally accepted to be approximately 30–100 L/m<Superscript>2</Superscript> in most individuals. This rather large volume of distribution is consistent with ∼98% of the drug being protein-bound. Polysorbate 80 in concentrations observed in patients treated with docetaxel is responsible for increasing the unbound fraction of docetaxel by 50% [<CitationRef CitationID="CR10_15">10</CitationRef>], resulting in greater exposure to docetaxel as well as greater likelihood of neutropenia [<CitationRef CitationID="CR11_15">11</CitationRef>, <CitationRef CitationID="CR12_15">12</CitationRef>]. It has been proposed that polysorbate 80 is able to form micelar complexes with proteins, including serum albumin and α1-acid glycoprotein causing saturable binding of docetaxel that has also been observed with other drugs [<CitationRef CitationID="CR13_15">13</CitationRef>, <CitationRef CitationID="CR14_15">14</CitationRef>], or by rapid degradation of polysorbate 80 by plasma esterases followed by oleic acid-mediated protein binding displacement of docetaxel [<CitationRef CitationID="CR15_15">15</CitationRef>]. Docetaxel is subjected to successive hydroxylation reactions by cytochrome P450 CYP3A4/5 at the C13 carbon on the <Emphasis Type="Italic">tert</Emphasis>-butyl sidechain resulting in hydroxy-docetaxel, two stereometric hydroxyoxazolidinones, and an oxazolidinone metabolite (called M1–M4, respectively), and approximately 75% of the drug is recovered in these relatively inactive metabolites [<CitationRef CitationID="CR16_15">16</CitationRef>] (Fig. <InternalRef RefID="Fig1">15.1</InternalRef>). Docetaxel is primarily eliminated by excretion into the bile with approximately 5–10% being cleared by urinary excretion.<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 15.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Docetaxel metabolic and transport pathway. Docetaxel-related intracellular pathways, uptake, metabolism, and elimination</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO1_15">
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_15_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">The importance of CYP3A enzymes on docetaxel metabolism was recently underscored in a study that found a sevenfold decrease in the clearance of docetaxel in mice lacking the <Emphasis Type="Italic">Cyp3a</Emphasis> gene cluster [<CitationRef CitationID="CR17_15">17</CitationRef>] and another study that found that individuals with certain high expression/function of <Emphasis Type="Italic">CYP3A</Emphasis> alleles had an approximate 64–75% increase in docetaxel clearance [<CitationRef CitationID="CR18_15">18</CitationRef>, <CitationRef CitationID="CR19_15">19</CitationRef>]. Both parent drug and docetaxel metabolites are transported across several biological barriers by the transporters ABCB1 [<CitationRef CitationID="CR20_15">20</CitationRef>], ABCC2 [<CitationRef CitationID="CR21_15">21</CitationRef>], and OATP1B3 [<CitationRef CitationID="CR22_15">22</CitationRef>] (see Fig. <InternalRef RefID="Fig1">15.1</InternalRef>). The current literature suggests that docetaxel is taken into the liver by OATP1B3, inactivated by CYP3A4/5, eliminated through hepatobilliary secretion by ABCB1 and ABCC2, and undergoes enterohepatic recirculation that is mediated by ABCB1 [<CitationRef CitationID="CR23_15">23</CitationRef>]. Such metabolism and transport characteristics have also been noted in peripheral tissues including blood–brain and blood–nerve barriers [<CitationRef CitationID="CR24_15">24</CitationRef>–<CitationRef CitationID="CR26_15">26</CitationRef>], within hematopoietic cells [<CitationRef CitationID="CR27_15">27</CitationRef>, <CitationRef CitationID="CR28_15">28</CitationRef>], and even within tumors themselves leading to multidrug resistance [<CitationRef CitationID="CR29_15">29</CitationRef>, <CitationRef CitationID="CR30_15">30</CitationRef>]. Moreover, the genes encoding the above enzymes and transporters are all regulated by the pregnane X receptor (PXR; NR1I2), the constitutive androstane receptor (CAR; NR1I3) nuclear receptors that promiscuously bind to many different xenobiotic substrates and modulate gene expression [<CitationRef CitationID="CR31_15">31</CitationRef>, <CitationRef CitationID="CR32_15">32</CitationRef>]. CYP1B1 also generates reactive estrogen species that may be responsible for docetaxel inefficacy by both interfering with docetaxel–microtubule interactions as well as covalently binding to docetaxel itself and reducing its potency [<CitationRef CitationID="CR33_15">33</CitationRef>, <CitationRef CitationID="CR34_15">34</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Nongenetic Sources of Variability in Docetaxel Pharmacology</Heading>
              <Para TextBreak="No">Docetaxel variability is manifested in an approximate 10% difference in docetaxel clearance among individuals [<CitationRef CitationID="CR35_15">35</CitationRef>], an approximate 10–35% lower clearance in women than in men [<CitationRef CitationID="CR18_15">18</CitationRef>, <CitationRef CitationID="CR36_15">36</CitationRef>, <CitationRef CitationID="CR37_15">37</CitationRef>], wide variability in systemic exposure [<CitationRef CitationID="CR38_15">38</CitationRef>], alterations in toxicity determined by PK and/or drug distribution [<CitationRef CitationID="CR39_15">39</CitationRef>, <CitationRef CitationID="CR40_15">40</CitationRef>], and ultimately alterations in progression and time to death [<CitationRef CitationID="CR40_15">40</CitationRef>, <CitationRef CitationID="CR41_15">41</CitationRef>]. To date, variability in PK has been evaluated in a variety of populations with several different diseases, and it has been noted that hepatic function, gender dimorphism, age, and plasma protein levels (especially the α-acid glycoprotein, AAG) are important determinants of PK and pharmacodynamics (PD) [<CitationRef CitationID="CR42_15">42</CitationRef>]. It is expected that drug coadministration, comorbidity, diet, and myriad other factors also influence docetaxel PK/PD, although these remain poorly studied. Pharmacokinetic modeling in patients has revealed that the most important factors in determining interindividual variation in docetaxel clearance (L/h) are body surface area (BSA; m<Superscript>2</Superscript>), age (years), AAG levels (g/L), albumin levels (g/L), and hepatic dysfunction affecting clearance of docetaxel (HEP12) as is shown in the following equation [<CitationRef CitationID="CR43_15">43</CitationRef>].
<Equation ID="Equa_15">
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="978-1-60327-829-4_15_Chapter_TeX2GIF_Equa_15.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                  <EquationSource Format="TEX"><![CDATA[
$$\begin{array}{ll}\text{CL} &=\text{BSA (}22.1-3.\text{55AAG}-0.0\text{95AGE}\\ & +0.\text{2245ALB)}\text(1-0.\text{334HEP12})\end{array}$$
]]></EquationSource>
                </Equation>
              </Para>
              <Para TextBreak="No">As the aforementioned model suggests, the binding of docetaxel to serum proteins and liver function is especially important to determining variability in docetaxel pharmacology. Docetaxel binds to albumin, AAG, and lipoproteins in the serum, is primarily metabolized in the liver, and cleared through the hepatobiliary route.</Para>
              <Para TextBreak="No">Liver function abnormalities are associated with reduced docetaxel clearance that is highly variable as compared to patients with normal liver function, and much of this variability can be attributed to a reduced CYP3A activity phenotype – especially in patients with advanced liver dysfunction [<CitationRef CitationID="CR11_15">11</CitationRef>, <CitationRef CitationID="CR44_15">44</CitationRef>]. However, liver metastases of prostate cancer are uncommon; therefore, liver impairment is not characteristic of this disease. Since AAG levels are highly variable in individuals with certain types of cancer as a result of proinflammatory pathways, AAG levels are also considered to be the very important determinants of variation in docetaxel plasma-protein binding properties [<CitationRef CitationID="CR45_15">45</CitationRef>]. Higher AAG levels are considered a surrogate for decreased unbound fraction available for elimination [<CitationRef CitationID="CR46_15">46</CitationRef>], an expected reduction in hematological toxicity [<CitationRef CitationID="CR11_15">11</CitationRef>], and a potential effect on nonhematological toxicity. Some have suggested that inflammation in the prostate may lead to prostate cancer, and that AAG can play a role in disease etiology [<CitationRef CitationID="CR47_15">47</CitationRef>, <CitationRef CitationID="CR48_15">48</CitationRef>]. A strong, nonsignificant trend does indeed exist where men with metastatic prostate cancer have elevated AAG, while African American and Caucasian men also have higher levels of AAG than men of other races [<CitationRef CitationID="CR49_15">49</CitationRef>, <CitationRef CitationID="CR50_15">50</CitationRef>]. However, it is unclear if AAG levels are clinically important covariates in docetaxel treatment of advanced prostate cancer, although this relationship has been demonstrated in non-small cell lung carcinoma – a disease with frequent liver involvement resulting in high AAG levels [<CitationRef CitationID="CR51_15">51</CitationRef>]. Finally, others have shown that castrate patients have a 50% higher clearance of docetaxel than noncastrate patients [<CitationRef CitationID="CR52_15">52</CitationRef>], resulting in increased likelihood of neutropenic events [<CitationRef CitationID="CR53_15">53</CitationRef>, <CitationRef CitationID="CR54_15">54</CitationRef>]. Therefore, hormonal factors may change the metabolism of docetaxel in males.</Para>
              <Para TextBreak="No">Since albumin, AAG, and CYP3A are of liver origin, no changes are expected in most cases of advanced prostate cancer although AAG levels might be higher. It should also again be noted that since men have a rapid clearance of docetaxel than women, and that docetaxel clearance is even higher in men with metastatic prostate cancer than in noncastrate patients, liver function differences might be less important in prostate cancer than in other diseases. This may change only if the patient has massive liver involvement, which is very uncommon.</Para>
              <Para TextBreak="No">Renal function is also not expected to be an important determinant of docetaxel PK/PD given that so little docetaxel is cleared through the urine (∼5–10%). Indeed, an individual with advanced renal disease receiving docetaxel at 65 mg/m<Superscript>2</Superscript> had similar pharmacokinetic parameters to patients without renal failure receiving the same treatment [<CitationRef CitationID="CR55_15">55</CitationRef>]. However, confirmation of these results in a larger patient cohort has not yet been published.</Para>
              <Para TextBreak="No">Several studies have related age to PK/PD parameters during docetaxel treatment. At the highest dose evaluated (75 mg/m<Superscript>2</Superscript>), docetaxel PK were unchanged, although docetaxel-induced neutropenia was higher in the elderly cohort (16%) than in the younger cohort (0%) [<CitationRef CitationID="CR56_15">56</CitationRef>]. Another study found that docetaxel toxicity is also increased in elderly patients while pharamacokinetics remain unchanged [<CitationRef CitationID="CR57_15">57</CitationRef>]. However, the aforementioned studies evaluated few elderly patients (<Emphasis Type="Italic">n</Emphasis> ≤ 26), and only a very small cohort of elderly patients with prostate cancer receiving single-agent docetaxel (<Emphasis Type="Italic">n</Emphasis> ≤ 6) was evaluated. Furthermore, both of these studies were in contrast to a larger pharmacokinetic study, where clearance was modestly related to age (estimated at a 7% decrease in mean clearance for a 71-year-old patient) [<CitationRef CitationID="CR58_15">58</CitationRef>]. Other studies have evaluated elderly patients with non-small cell lung carcinoma and found that docetaxel at a dose of (30–60 mg/m<Superscript>2</Superscript>) is well tolerated alone or in combination with cisplatin [<CitationRef CitationID="CR59_15">59</CitationRef>–<CitationRef CitationID="CR61_15">61</CitationRef>]. Thus, age might be associated with interindividual differences in docetaxel-related toxicity in a dose/schedule-dependant fashion, but age may only be modestly associated with PK.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Docetaxel Pharmacogenetics</Heading>
              <Para TextBreak="No">Several pharmacogenetic studies have been completed studying genetic variation in docetaxel disposition genes including <Emphasis Type="Italic">ABCB1</Emphasis>, <Emphasis Type="Italic">ABCC2</Emphasis>, <Emphasis Type="Italic">ABCG2</Emphasis>, <Emphasis Type="Italic">CYP1B1</Emphasis>, <Emphasis Type="Italic">CYP3A4/5</Emphasis>, <Emphasis Type="Italic">NR1I2</Emphasis>, <Emphasis Type="Italic">NR1I3</Emphasis>, and <Emphasis Type="Italic">SLCO1B3</Emphasis> (encoding OATP1B3). The results from these studies will be summarized below in the following sections.</Para>
              <Section3 ID="Sec7">
                <Heading>CYP3A4 and CYP3A5</Heading>
                <Para TextBreak="No">Several have evaluated the <Emphasis Type="Italic">CYP3A4*1B</Emphasis> and <Emphasis Type="Italic">CYP3A5*3C</Emphasis> polymorphisms in relation to the PK of docetaxel. Most studies in this regard have been negative [<CitationRef CitationID="CR62_15">62</CitationRef>–<CitationRef CitationID="CR68_15">68</CitationRef>], although recent evidence suggests that these SNPs may be important when considered in the context of <Emphasis Type="Italic">CYP3A4/5</Emphasis> haplotype [<CitationRef CitationID="CR18_15">18</CitationRef>, <CitationRef CitationID="CR19_15">19</CitationRef>]. Baker et al. found that carriers of a haplotype consisting of <Emphasis Type="Italic">CYP3A4*1B</Emphasis> (i.e., variant at rs2740574) and <Emphasis Type="Italic">CYP3A5*1A</Emphasis> alleles (i.e., wild type at <Emphasis Type="Italic">CYP3A5*3C</Emphasis>; rs776746) that was named <Emphasis Type="Italic">CYP3A4/5*2</Emphasis> had a 64% higher clearance of docetaxel and a 46% increase in clearance of another CYP3A4/5 substrate, midazolam. Those individuals (<Emphasis Type="Italic">n</Emphasis> = 5) carrying the <Emphasis Type="Italic">CYP3A4/5*2</Emphasis> haplotype may actually have a higher level of CYP3A expression in the liver due to increases in CYP3A4 expression brought on by the <Emphasis Type="Italic">CYP3A4*1B</Emphasis> allele [<CitationRef CitationID="CR69_15">69</CitationRef>], coupled with CYP3A5 expression in the liver in those patients not carrying the <Emphasis Type="Italic">CYP3A5*3</Emphasis> null allele. Another study in Caucasians had similar results with those individuals carrying <Emphasis Type="Italic">CYP3A4*1B</Emphasis> and <Emphasis Type="Italic">CYP3A5*1A</Emphasis> alleles having a 75% increase in docetaxel clearance, although this relationship depended on clearance data from only four patients [<CitationRef CitationID="CR19_15">19</CitationRef>].</Para>
                <Para TextBreak="No">It is important to note that the above findings cannot be extrapolated to other world populations as the haplotype is organized in a different fashion in non-Caucasians, and future investigations evaluating this haplotype must take interracial genetic variation into account. However, most investigations in the Caucasian population taking place prior to these studies did not evaluate the effect of <Emphasis Type="Italic">CYP3A4/5</Emphasis> haplotypes that might be better associated with clearance of substrate drugs, or outcome following treatment [<CitationRef CitationID="CR62_15">62</CitationRef>, <CitationRef CitationID="CR63_15">63</CitationRef>, <CitationRef CitationID="CR65_15">65</CitationRef>, <CitationRef CitationID="CR68_15">68</CitationRef>]. Those studies in the Asian population suffered from very low power due to <Emphasis Type="Italic">CYP3A4/5</Emphasis> monomorphism [<CitationRef CitationID="CR67_15">67</CitationRef>], or low frequency of these SNPs in the Asian population [<CitationRef CitationID="CR64_15">64</CitationRef>, <CitationRef CitationID="CR66_15">66</CitationRef>] and are thus inconclusive or difficult to interpret. African Americans also have a different haplotype organization, and no relationship has been found between <Emphasis Type="Italic">CYP3A4/5</Emphasis> SNPs and docetaxel PK/PD in this racial population [<CitationRef CitationID="CR68_15">68</CitationRef>]. In summary, the haplotype structure of <Emphasis Type="Italic">CYP3A4/5</Emphasis> is very likely an important determinant of pharmacogenetics relationships between these enzymes and docetaxel PK/PD in Caucasians, and <Emphasis Type="Italic">CYP3A4/5</Emphasis> haplotypes remain poorly studied in relation to docetaxel PK/PD in all world populations.</Para>
              </Section3>
              <Section3 ID="Sec8">
                <Heading>The ABCB1, ABCC2, ABCG2, and OATP1B3 Active Transporters of Docetaxel</Heading>
                <Para TextBreak="No">Pharmacogenetics studies in active transporters in docetaxel treatment are quite complex as docetaxel transport seems to be responsible for drug distribution throughout the body including in and out of blood–brain/nerve barriers, hematopoeitic cells, enterocytes, and liver cells. For this reason, all of the aforementioned transporters might determine local drug levels in addition to overall PK of docetaxel; thus, genetic variation within this pathway might influence several tissues in a different fashion.</Para>
                <Para TextBreak="No">Earlier studies found that <Emphasis Type="Italic">ABCB1</Emphasis> polymorphisms were associated with clearance of docetaxel and midazolam [<CitationRef CitationID="CR62_15">62</CitationRef>, <CitationRef CitationID="CR64_15">64</CitationRef>] and docetaxel toxicity [<CitationRef CitationID="CR19_15">19</CitationRef>]. Still other studies found no relationship between docetaxel PK and ABCB1 SNPs [<CitationRef CitationID="CR19_15">19</CitationRef>, <CitationRef CitationID="CR67_15">67</CitationRef>]. Since Kimchi-Sarfaty et al. published rather convincing evidence that <Emphasis Type="Italic">ABCB1</Emphasis> haplotypes are related to protein folding and expression in a fashion that is more deterministic that any individual <Emphasis Type="Italic">ABCB1</Emphasis> SNP alone, two studies have investigated the combined effect of ABCB1 SNPs at the 1236C&gt;T, 2677G&gt;T/A, and 3435C&gt;T loci.</Para>
                <Para TextBreak="No">Studies that investigated <Emphasis Type="Italic">ABCB1</Emphasis> 1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T SNPs alone and in diplotype combinations found that patients with castration-resistant prostate cancer (CRPC) receiving docetaxel alone and who carried 1236C-2677G-3435C linked alleles had improved overall survival, while patients carrying the 2677T-3435T diplotype had shorter median survival after treatment. Interestingly, patients with the 2677T-3435T haplotype also had higher on-study PSA that might be related to survival as those patients who had a higher disease burden. However, it may be that patients carrying certain <Emphasis Type="Italic">ABCB1</Emphasis> diplotypes had tumors that were more resistant to docetaxel therapy or alterations in clearance that were responsible for this relationship. However, no relationship with clearance was observed in a separate cohort of patients treated with docetaxel in this study, and other studies have found relationships with docetaxel outcomes that are independent of PK [<CitationRef CitationID="CR19_15">19</CitationRef>]. The present study also found that patients treated with docetaxel in combination with thalidomide (not an ABCB1 substrate) had an increased likelihood to develop early onset neuropathy, while there was no relationship found in those treated with docetaxel alone. This is probably because thalidomide also causes neuropathies resulting in a higher neuropathy burden in the combination arm. Thus, small differences in efflux of docetaxel from nerve tissues due to <Emphasis Type="Italic">ABCB1</Emphasis> SNPs may contribute to onset of neuropathy in these patients. Finally, a trend toward increased neutropenia grade was also observed in patients homozygous for the 2677T-3435T haplotype. This study suggests that <Emphasis Type="Italic">ABCB1</Emphasis> SNPs contribute to survival and toxicity differences in men with CRPC and again demonstrates that haplotype analysis is important to determine associations with polymorphisms in docetaxel disposition genes and clinical outcome. A second study investigated variation in both individual genotypes and in the common haplotypes within <Emphasis Type="Italic">ABCB1</Emphasis> (1236C&gt;T, 2677G&gt;T/A, 3435C&gt;T), <Emphasis Type="Italic">ABCC2</Emphasis> (–1019A&gt;G, –24C&gt;T, 1249G&gt;A, IVS26 –34C&gt;T, 3972C&gt;T, 4544G&gt;A), and <Emphasis Type="Italic">SLCO1B3</Emphasis> (334T&gt;G, 439A&gt;G, 699G&gt;A, 767G&gt;C, 1559A&gt;C, 1679T&gt;C) against docetaxel clearance data in Caucasian patients with various malignancies, including 24 patients with prostate cancer. None of the genotypes or haplotypes were related to docetaxel PK, as was consistent with the former study.</Para>
                <Para TextBreak="No">Other known docetaxel transporters have been less studied. The <Emphasis Type="Italic">ABCC2</Emphasis> rs12762549 SNP has been linked to docetaxel-induced neutropenia in the Asian population [<CitationRef CitationID="CR67_15">67</CitationRef>], although no associations between <Emphasis Type="Italic">ABCC2</Emphasis> polymorphisms, alone or in haplotype, have been found in relation to docetaxel PK [<CitationRef CitationID="CR18_15">18</CitationRef>]. Similar results were found for SNPs in <Emphasis Type="Italic">SLCO1B3</Emphasis>. Interestingly, the protein product of <Emphasis Type="Italic">SLCO1B3</Emphasis> (OATP1B3) is upregulated during prostate cancer progression [<CitationRef CitationID="CR70_15">70</CitationRef>, <CitationRef CitationID="CR71_15">71</CitationRef>], although no study has linked <Emphasis Type="Italic">SLCO1B3</Emphasis> SNPs to docetaxel efficacy in this disease. Finally, the <Emphasis Type="Italic">ABCG2</Emphasis> Q141K polymorphism was associated with improved survival following treatment with combination docetaxel and vinorelbine or combination docetaxel and estramustine in men with CRPC [<CitationRef CitationID="CR65_15">65</CitationRef>]. The authors concluded that the increase in survival was related to inefficiency of the drug efflux pump leading to increased efficacy in some patients. However, since docetaxel is not an ABCG2 substrate [<CitationRef CitationID="CR72_15">72</CitationRef>], it is likely that ABCG2 effluxes another substrate that lowers docetaxel efficacy, or that decreases in ABCG2 pump efficiency brought on by the Q141K SNP [<CitationRef CitationID="CR73_15">73</CitationRef>] can alter the efflux of a substrate that is related to cancer progression (e.g., PhIP).</Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Other Docetaxel Pharmacogenetics Studies</Heading>
              <Para TextBreak="No">Some studies have attempted to link docetaxel PK to polymorphisms in <Emphasis Type="Italic">PXR</Emphasis>, <Emphasis Type="Italic">CAR</Emphasis>, and <Emphasis Type="Italic">HNF4α</Emphasis> in the Asian population [<CitationRef CitationID="CR66_15">66</CitationRef>, <CitationRef CitationID="CR74_15">74</CitationRef>]. The rationale for such studies is explained in Fig. <InternalRef RefID="Fig1">15.1</InternalRef> where nuclear receptors bind to docetaxel and increase the expression of genes related to docetaxel metabolism and transport. Such nuclear receptors are thus responsible for global regulation of genes involved in docetaxel disposition. While no such study has found a relationship with PK, a relationship between the Met49Val SNP in <Emphasis Type="Italic">HNF4α</Emphasis>and slower neutrophil recovery was observed [<CitationRef CitationID="CR66_15">66</CitationRef>]. This same study found that patients who were wild type for both <Emphasis Type="Italic">HNF4α</Emphasis> Met49Val and <Emphasis Type="Italic">CAR</Emphasis> Pro180Pro had an approximate 16% lower percentage neutrophil decrease from baseline. Thus, it seems that while <Emphasis Type="Italic">PXR</Emphasis> and <Emphasis Type="Italic">CAR</Emphasis> are polymorphic, the SNPs in these genes have not yet been found to be responsible for any detectible interindividual variation in relation to docetaxel. However, genetic variation in <Emphasis Type="Italic">HNF4α</Emphasis>, which regulates genes involved in cell growth and survival, might be responsible for the robustness of neutrophils when challenged by docetaxel treatment, and this might be related to variation in <Emphasis Type="Italic">PXR/CAR</Emphasis>. Further study is needed to both validate the above study and elucidate the molecular reasons behind these associations.</Para>
              <Para TextBreak="No">CYP1B1 has also been found to be related to docetaxel treatment. Early studies indicated that CYP1B1 might directly metabolize docetaxel [<CitationRef CitationID="CR75_15">75</CitationRef>], although a later study indicated rather convincingly that this was not true [<CitationRef CitationID="CR76_15">76</CitationRef>]. However, CYP1B1 was found to be highly expressed in the prostate tumors and seemed to be related to docetaxel treatment [<CitationRef CitationID="CR34_15">34</CitationRef>, <CitationRef CitationID="CR77_15">77</CitationRef>]. Three studies have been published that have indicated that the <Emphasis Type="Italic">CYP1B1</Emphasis> L432V (<Emphasis Type="Italic">CYP1B1*3</Emphasis>) allele might be associated with docetaxel treatment efficacy in prostate cancer [<CitationRef CitationID="CR33_15">33</CitationRef>, <CitationRef CitationID="CR78_15">78</CitationRef>, <CitationRef CitationID="CR79_15">79</CitationRef>]. This relationship is likely due to more efficient metabolism of estrogen by individuals carrying the <Emphasis Type="Italic">CYP1B1*3</Emphasis> allele, resulting in increased levels of reactive estrogen metabolites that antagonize docetaxel by destablizing tubulin and directly adducting docetaxel itself. Indeed, higher levels of CYP1B1 estrogen metabolites have been observed in the urine of men with prostate cancer [<CitationRef CitationID="CR80_15">80</CitationRef>]. However, further studies are required to validate these data in the clinic and in the laboratory.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Mitoxantrone</Heading>
            <Section2 ID="Sec11">
              <Heading>Mechanism of Action</Heading>
              <Para TextBreak="No">Anthracycline antibiotics, including mitoxantrone, are responsible for several different biological effects related to their role as anticancer agents. The main mechanism behind the antineoplastic effect of these agents is inhibition of topoisomerase II (TOPOII) resulting in inhibition of DNA repair [<CitationRef CitationID="CR81_15">81</CitationRef>]. Mitoxantrone also inhibits DNA replication and DNA-dependent RNA synthesis in its role as a DNA intercalating agent, DNA replication through inhibition of nuclear helicase, and can undergo reduction reactions resulting in the formation of quinone species that damage cellular components [<CitationRef CitationID="CR82_15">82</CitationRef>, <CitationRef CitationID="CR83_15">83</CitationRef>]. However, mitoxantrone is significantly less reactive than other anthracyclines and thus does not form free radical intermediates as readily. For this reason, it is also less likely to cause cardiotoxicity, and higher dosages can be given without increasing the risk of cardiac failure [<CitationRef CitationID="CR84_15">84</CitationRef>]. Mitoxantrone has been observed bound to DNA, and it accumulates in the endoplasmic reticulum, cytosol, and in low-polarity environments consistent with cell membranes [<CitationRef CitationID="CR85_15">85</CitationRef>]. Unlike other cytotoxic agents, mitoxantrone cytotoxicity is cell cycle-independent, killing both proliferating and nonproliferating cells alike [<CitationRef CitationID="CR86_15">86</CitationRef>]. Mitxantrone plus steroidal therapy has been used for the treatment of CRPC for its palliative effects, but this therapy does not increase life expectancy [<CitationRef CitationID="CR87_15">87</CitationRef>–<CitationRef CitationID="CR89_15">89</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec12">
              <Heading>Pharmacokinetics, Drug Distribution, and Pharmacodynamic Determinants</Heading>
              <Para TextBreak="No">There is an approximate 13-fold interindividual variation in the area under the curve (AUC) exposure following mitoxantrone in patients with acute lympho-blastic leukemia (ALL) receiving 5 mg/m<Superscript>2</Superscript> every week for 3 weeks [<CitationRef CitationID="CR90_15">90</CitationRef>]. A population PK model demonstrated an approximately 46% interindividual variability in clearance [<CitationRef CitationID="CR91_15">91</CitationRef>]. For men suffering from CRPC, mitoxantrone is typically given at a dose level of 12 mg/m<Superscript>2</Superscript> every 3 weeks in combination with steroids such as prednisone. Mitoxantrone is distributed rapidly and extensively into the tissues while ∼78% of the drug is protein bound. Two major mono- and dicarboxylic acid metabolites have been observed, although several metabolites are present. The primary routes of elimination of mitoxantrone include hepatobilliary (∼25% over 5 days) and urinary excretion (6–11%; 65% of drug is unchanged).</Para>
              <Para TextBreak="No">Mitoxantrone is extruded from cells expressing the ATP-binding cassette transporters ABCB1 (MDR1, P-glycoprotein) [<CitationRef CitationID="CR92_15">92</CitationRef>], ABCC1 (MRP1) [<CitationRef CitationID="CR93_15">93</CitationRef>–<CitationRef CitationID="CR95_15">95</CitationRef>], ABCC2 (MRP2) [<CitationRef CitationID="CR96_15">96</CitationRef>], and ABCG2 (BCRP, MXR, ABCP) [<CitationRef CitationID="CR97_15">97</CitationRef>, <CitationRef CitationID="CR98_15">98</CitationRef>], and it is also actively influxed into certain cells via an unknown mechanism [<CitationRef CitationID="CR99_15">99</CitationRef>]. Whereas these transporters are expressed in hepatic and renal cells, they could mediate mitoxantrone elimination pathways, and some of these transporters limit penetration of anthracyclines into certain tissues such as hematopoietic stem cells, thereby limiting toxicity [<CitationRef CitationID="CR25_15">25</CitationRef>]. Prostate tumors frequently upregulate ATP-binding cassette (ABC) transporters, such as ABCB1 and ABCG2 [<CitationRef CitationID="CR100_15">100</CitationRef>, <CitationRef CitationID="CR101_15">101</CitationRef>], during the course of tumor progression. It is likely that resistance to mitoxantrone occurs due to multidrug resistance brought on by overexpression of active drug transporters. Overexpression of these transporters seems to be related to prolonged androgen deprivation [<CitationRef CitationID="CR101_15">101</CitationRef>, <CitationRef CitationID="CR102_15">102</CitationRef>], acquired resistance to mitoxantrone [<CitationRef CitationID="CR103_15">103</CitationRef>], and the ability of normal and tumor stem cells to evade cytotoxicity [<CitationRef CitationID="CR101_15">101</CitationRef>, <CitationRef CitationID="CR104_15">104</CitationRef>]. It is also possible that downregulation of an uncharacterized influx mechanism could also be responsible for mitoxantrone resistance, although this remains to be explored [<CitationRef CitationID="CR99_15">99</CitationRef>]. The pathways that regulate mitoxantrone metabolism have not yet been elucidated.</Para>
            </Section2>
            <Section2 ID="Sec13">
              <Heading>Nongenetic Sources of Variability in Pharmacology</Heading>
              <Para TextBreak="No">Mitoxantrone clearance is reduced in patients with hepatic dysfunction, and patients with normal hepatic function with bilirubin &gt;3.4 mg/dL have a threefold increase in AUC exposure following mitoxantrone. Thus, dose adjustments are required in patients with moderate to severe hepatic dysfunction. Advanced age does not appear to be related to mitoxantrone toxicity or outcome as the drug was well tolerated with similar response in patients with ALL &gt;60 years of age at both high (80 mg/m<Superscript>2</Superscript>; day 2) and low (12 mg/m<Superscript>2</Superscript>; days 1–3) doses [<CitationRef CitationID="CR105_15">105</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec14">
              <Heading>Pharmacogenetics</Heading>
              <Para TextBreak="No">The common <Emphasis Type="Italic">ABCG2</Emphasis> 421C&gt;A (Q141K) variant has been attributed to lowered expression of ABCG2 [<CitationRef CitationID="CR106_15">106</CitationRef>–<CitationRef CitationID="CR110_15">110</CitationRef>]. The Q141K polymorphism is responsible for an approximate two- to fivefold increase in drug sensitivity toward mitoxantrone in vitro as compared to the wild-type protein in four separate studies [<CitationRef CitationID="CR73_15">73</CitationRef>, <CitationRef CitationID="CR106_15">106</CitationRef>, <CitationRef CitationID="CR111_15">111</CitationRef>, <CitationRef CitationID="CR112_15">112</CitationRef>]. The <Emphasis Type="Italic">ABCG2</Emphasis> 34G&gt;A (V12M) allele has been linked to poor localization of ABCG2 resulting in a less functional protein [<CitationRef CitationID="CR73_15">73</CitationRef>], while a small proportion of the Japanese population (∼2%) carries the <Emphasis Type="Italic">ABCG2</Emphasis> 376C&gt;T (Q126stop) transition that results in protein truncation and a complete loss of ABCG2 function [<CitationRef CitationID="CR106_15">106</CitationRef>]. The V12M polymorphism was not associated with increased mitoxantrone sensitivity vs. the wild-type allele when expressed in PA137 and Flp-ln-293 cells [<CitationRef CitationID="CR106_15">106</CitationRef>, <CitationRef CitationID="CR112_15">112</CitationRef>], but it abolished the effect of ABCG2 expression in LLC-PK1 cells treated with mitoxantrone [<CitationRef CitationID="CR73_15">73</CitationRef>]. Some speculate that the Q126stop truncation increases sensitivity through drastically lowering ABCG2 expression [<CitationRef CitationID="CR106_15">106</CitationRef>, <CitationRef CitationID="CR113_15">113</CitationRef>], although no data have emerged to support this conclusion. Other alleles have been explored that are only found in small proportions of certain world populations or are only present in cancer cell lines [<CitationRef CitationID="CR106_15">106</CitationRef>, <CitationRef CitationID="CR112_15">112</CitationRef>, <CitationRef CitationID="CR114_15">114</CitationRef>, <CitationRef CitationID="CR115_15">115</CitationRef>], but it is unclear if any of these are relevant to clinical treatment with mitoxantrone. Further, while ABC-transporter polymorphisms have been related to the PK of numerous anticancer drugs [<CitationRef CitationID="CR116_15">116</CitationRef>], ABCG2 and ABCB1 mRNA levels have been related to mitoxantrone treatment outcome in cancer [<CitationRef CitationID="CR117_15">117</CitationRef>], and ABCG2 was even initially discovered as a mediator of mitoxantrone resistance in cancer cell lines [<CitationRef CitationID="CR97_15">97</CitationRef>, <CitationRef CitationID="CR98_15">98</CitationRef>], no clinical studies evaluating the relationship between transporter polymorphisms and mitoxantrone pharmacology have yet been published (based on a PubMed search of “transporter polymorphism mitoxantrone” revealing 22 articles; conducted December 19, 2008).</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec15">
            <Heading>Estramustine</Heading>
            <Section2 ID="Sec16">
              <Heading>Mechanism of Action</Heading>
              <Para TextBreak="No">Estramustine phosphate is a nor-nitrogen mustard-carbamate estradiol that is administered to men with prostate cancer. The initial design of estramustine targeted hormone-dependent cancers where estramustine was thought to bind hormone receptors and mediate DNA alkylation in the nucleus through the mustard-carbamate moiety [<CitationRef CitationID="CR118_15">118</CitationRef>]. Interestingly, the drug has little (if any) alykylating activity, and intact estramustine does not bind to hormone receptors. Estramustine does increase the levels of estradiol through hydrolysis of the nitrogen mustard moiety, thus increasing estradiol binding to the estrogen receptor [<CitationRef CitationID="CR119_15">119</CitationRef>]. Like mitoxantrone, estramustine has a range of biological effects that suppress cell growth in prostate tumors, and these include direct cytotoxicity, inhibition of mitosis, promotion of apoptosis, microtubule depolymerization, inhibition of DNA synthesis, TOPOII inhibition, blockade of tyrosine kinase, disruption of apoptotic regulators such as bcl-2, activation of death domain receptors (as reviewed by Ho et al. [<CitationRef CitationID="CR120_15">120</CitationRef>]), formation of oxygen radicals [<CitationRef CitationID="CR121_15">121</CitationRef>], and interaction with nuclear matrix proteins [<CitationRef CitationID="CR122_15">122</CitationRef>, <CitationRef CitationID="CR123_15">123</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Pharmacokinetics, Drug Distribution, and Pharmacodynamic Determinants</Heading>
              <Para TextBreak="No">Estramustine phosphate is administered to men with prostate cancer orally at a dose level of approximately 300 mg twice daily. Most of the estramustine phosphate is retained within the body following drug administration. Estramustine phosphate is rapidly dephosphorylated to estramustine most likely through alkaline phosphatase found in nearly every tissue [<CitationRef CitationID="CR124_15">124</CitationRef>], and oral estramustine is subject to heavy first-pass metabolism through this mechanism. As such, the oral bioavailability of intact estramustine phosphate is low (∼44–75%) with the majority of the drug being converted into other metabolites [<CitationRef CitationID="CR121_15">121</CitationRef>]. The dephosphorylated form (estramustine) is then oxidized to an estrone-bound mustard carbamate group (estromustine), and the carbamate–ester bond is subsequently hydrolyzed by carbaminidase forming estrone and a free carbamate mustard. All of these metabolic events, with the exception of the formation of estromustine, can take place in the prostate leading to an anticancer effect as previously explained. Following oral delivery, estromustine is the main metabolite found in plasma at an approximately 10- to 16-fold greater concentration than estramustine, while within tumors the estromustine:estramustine is approximately 2:1 [<CitationRef CitationID="CR121_15">121</CitationRef>], and estramustine has more potent anticancer activity than estromustine [<CitationRef CitationID="CR125_15">125</CitationRef>]. Targeting to the prostate is perhaps due to the estramustine-binding protein (EMBP) being expressed within that tissue [<CitationRef CitationID="CR126_15">126</CitationRef>]. Following a single dose of estramustine phosphate (420 mg), the peak plasma concentration of estromustine (<Emphasis Type="Italic">C</Emphasis>
                <Subscript>max</Subscript>) is achieved after approximately 2–3 h (∼310–475 µg/mL in the plasma), and the plasma half-life of this metabolite is approximately 14 h [<CitationRef CitationID="CR127_15">127</CitationRef>]. Following carbaminidase metabolism, the liberated estrogen increases the levels of estradiol within a range similar to conventional estradiol therapy. Similar to endogenous estrogens, estramustine estrogen metabolites are cleared through the hepatobilliary and urinary routes, although at a slower rate due to the heavy tissue retention of the drug. Little is known as to the fate of the free mustard group [<CitationRef CitationID="CR127_15">127</CitationRef>]. Estramustine also increases the levels of sex-hormone-binding globulin (SHBG), elevation of plasma transcortin and cortisol, suppression of adrenocorticotropic hormone (ACTH) by the pituitary, and subsequent reduction in leutenizing hormone (as reviewed in [<CitationRef CitationID="CR118_15">118</CitationRef>]).</Para>
            </Section2>
            <Section2 ID="Sec18">
              <Heading>Nongenetic Sources of Variability in Pharmacology</Heading>
              <Para TextBreak="No">The only well-studied source of variability in estramustine pharmacology has been in those individuals ingesting sources of calcium (e.g., milk and antacids) following an oral dose of estramustine. Absorption through the gastrointestinal tract is significantly inhibited by calcium, and the accumulation of estramustine and estromustine in tumors (glioma and astrocytoma) is significantly inhibited [<CitationRef CitationID="CR121_15">121</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec19">
              <Heading>Pharmacogenetics</Heading>
              <Para TextBreak="No">There have been few studies evaluating the pharmacogenetics of estramustine. Although a clinical trial was published demonstrating that ABCG2 Q141K was related to a more favorable clinical outcome following a combination of docetaxel and estramustine, it is unclear why this relationship exists [<CitationRef CitationID="CR65_15">65</CitationRef>]. The V158M polymorphism in catechol-<Emphasis Type="Italic">O</Emphasis>-methyltransferase (COMT) has been also been related to PSA-progression-free survival in men with prostate cancer, and the authors attribute this result to decreased formation of the microtubule-stabilizing agent 2-methoxyestradiol (2-ME) brought on by metabolism of estramustine-generated estrogens within prostate tumors [<CitationRef CitationID="CR128_15">128</CitationRef>]. It is also likely that this result is actually due to decreased conjugation of catechol estrogens within the prostate preventing their oxidation into procarcinogenic quinones and semiquinones [<CitationRef CitationID="CR129_15">129</CitationRef>, <CitationRef CitationID="CR130_15">130</CitationRef>]. Finally, another study found that the risk of estramustine-induced peripheral edema and appetite loss was related to polymorphisms in the <Emphasis Type="Italic">type 7 17β-hydroxysteroid dehydrogenase</Emphasis> (<Emphasis Type="Italic">HSD17B7</Emphasis>) gene in men with prostate cancer [<CitationRef CitationID="CR131_15">131</CitationRef>]. Again, it is very difficult to understand why this might be as so little is known about HSD17B7 and its involvement in steroidogenesis or the formation of sex hormones.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec20">
            <Heading>Satraplatin</Heading>
            <Section2 ID="Sec21">
              <Heading>Mechanism of Action</Heading>
              <Para TextBreak="No">Satraplatin, like other platinum-based chemotherapies (cisplatin, carboplatin, oxaloplatin), mediates its effects by binding to the DNA and forming inter- and intrastrand cross-links at adjacent purine bases, thus distorting the DNA template and preventing DNA replication. These compounds can also form mono-adducts to the DNA and bind to reactive thiols, amino, hydroxyl, or other groups on proteins and other cellular factors resulting in DNA–protein and other types of adducts (as reviewed in [<CitationRef CitationID="CR132_15">132</CitationRef>]). Such DNA binding often results in cell cycle arrest in the G2 phase and also activates several intracellular signaling pathways such those involved in DNA-damage repair, cell cycle arrest, and apoptosis [<CitationRef CitationID="CR133_15">133</CitationRef>–<CitationRef CitationID="CR135_15">135</CitationRef>]. The major active metabolite of satraplatin (JM118) is very similar to cisplatin except for a single cyclohexamine (instead of amine) moiety that contributes to its asymmetrical binding of the DNA. While JM118 still forms the aforementioned cross-links within DNA, chiral adducts can cause different DNA conformations and be processed differentially by intracellular machinery [<CitationRef CitationID="CR136_15">136</CitationRef>]. For example, satraplatin adducts evade the mismatch repair (MMR) pathway that is associated with resistance to cisplatin [<CitationRef CitationID="CR137_15">137</CitationRef>]. However, the X-ray crystal structure of the major satraplatin–DNA adduct has a remarkably similar structure to that of <Emphasis Type="Italic">cis</Emphasis>- and oxaloplatin [<CitationRef CitationID="CR138_15">138</CitationRef>], and both adducts are efficiently repaired by the nucleotide excision repair (NER) pathway [<CitationRef CitationID="CR139_15">139</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec22">
              <Heading>Pharmacokinetics, Drug Distribution, and Pharmacodynamic Determininants</Heading>
              <Para TextBreak="No">Following oral administration, satraplatin is absorbed through the gastrointestinal mucosa and undergoes rapid deacetylation to form the major active satraplatin metabolite JM118 that accounts for ∼20–40% of the administered platinum [<CitationRef CitationID="CR140_15">140</CitationRef>]. This deacetylation reaction is rather rapid as parent satraplatin has a half-life of only 6.3 min in whole blood in vitro to form JM118 and at least five other metabolites [<CitationRef CitationID="CR141_15">141</CitationRef>]. The majority of a dose of satraplatin becomes bound to red blood cells (∼62%) while 38% is found in plasma. Of the plasma fraction, 71% of the platinum content is bound to proteins (especially albumin) and the remaining 29% is unbound [<CitationRef CitationID="CR141_15">141</CitationRef>].</Para>
              <Para TextBreak="No">Satraplatin was originally developed in the search for a platinum-based drug with significant oral bioavailability with a similar toxicity profile to carboplatin (i.e., dose-limiting toxicities including myelosuppression) instead of the more toxic cisplatin (i.e., dose-limiting toxicities are nephro- and GI toxicity) [<CitationRef CitationID="CR142_15">142</CitationRef>]. As such it has rather higher bioavailability than other platinum drugs (i.e., cisplatin, carboplatin, and oxaloplatin). Satraplatin was also developed with the aim to find platinum species that can overcome cisplatin resistance mechanisms, and satraplatin evades certain pathways that confer resistance in human cell lines [<CitationRef CitationID="CR142_15">142</CitationRef>]. First, satraplatin demonstrates activity in cells that do not express the copper-ion uptake transporter CRT1, although forced expression of the copper efflux transporters ATP7A and ATP7B conferred resistance to JM118 [<CitationRef CitationID="CR143_15">143</CitationRef>]. As was previously mentioned, JM118 also evades the MMR pathway and thus confers partial resistance in tumor cell lines that upregulate repair pathways to overcome cisplatin cytotoxicity, as was noted by Kelland et al<Emphasis Type="Italic">.</Emphasis> [<CitationRef CitationID="CR144_15">144</CitationRef>]. However, since JM118 and cisplatin are removed with similar kinetics by the NER pathway [<CitationRef CitationID="CR139_15">139</CitationRef>], and JM-118 lesions are repairable when bound to certain genes [<CitationRef CitationID="CR134_15">134</CitationRef>], it appears that the partial resistance to JM118 noted by Kelland et al<Emphasis Type="Italic">.</Emphasis> was only due to MMR evasion [<CitationRef CitationID="CR142_15">142</CitationRef>]. Resistance to satraplatin or JM118 appears to be mediated by increased levels of glutathione [<CitationRef CitationID="CR133_15">133</CitationRef>] and increased intracellular detoxification mechanisms [<CitationRef CitationID="CR145_15">145</CitationRef>].</Para>
              <Para TextBreak="No">Unlike other platinum compounds. JM118 demonstrates activity in prostate cancer cells with a IC<Subscript>50</Subscript> of approximately 0.5–1.0 µM, although oxaliplatin has a slightly higher activity toward cytotoxicity in cells with a functional androgen receptor (LNCaP), and the activity of JM118 is similar to cisplatin in androgen-independent cell lines (PC3 and DU145) [<CitationRef CitationID="CR146_15">146</CitationRef>]. Yet, cisplatin and other platinum-based therapies have typically not demonstrated clinically significant therapeutic outcome in men with CRPC [<CitationRef CitationID="CR147_15">147</CitationRef>]. This may explain the recent findings of the SPARC (Satraplatin and Prednisone Against Refractory Cancer) trial where satraplatin was found to only have a palliative effect as overall survival in CRPC was not different between patients treated with satraplatin plus prednisone, or prednisone alone [<CitationRef CitationID="CR150_15">150</CitationRef>]. However, satraplatin has been shown to confer sensitivity to taxane treatment [<CitationRef CitationID="CR145_15">145</CitationRef>] and shows synergistic activity with docetaxel in vivo [<CitationRef CitationID="CR148_15">148</CitationRef>]. Moreover, satraplatin is able to evade docetaxel mechanisms of resistance such as the upregulation of multidrug resistance transporters (e.g., ABCB1, ABCC1/2) that remove docetaxel, but not satraplatin, from prostate cancer cells [<CitationRef CitationID="CR146_15">146</CitationRef>]. Although there are currently trials treating patients with the combination docetaxel plus satraplatin, it remains to be seen if the combination docetaxel plus satraplatin shows clinical benefit despite the undesirable results of satraplatin as monotherapy in hormone-resistant prostate cancer.</Para>
            </Section2>
            <Section2 ID="Sec23">
              <Heading>Nongenetic Sources of Variability in Pharmacology</Heading>
              <Para TextBreak="No">Satraplatin inhibits several cytochrome P450 enzymes such as CYP1A1, CYP1A2, CYP2A6, CYP2C8, CYP2D6, CYP2E1, and CYP3A4 [<CitationRef CitationID="CR149_15">149</CitationRef>]. This inhibition was noncompetitive and occurred with low IC50 values (∼1.0 µM for metabolite formation of testosterone and paclitaxel, respectively). However, the potential drug–drug and gene–drug interactions have not been well studied in the literature. It is expected that since satraplatin inhibits so many drug-metabolizing enzymes, cotreatment with other medications will be complicated by such interactions.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec24" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Prostate cancer has been treated using several different classes of drugs with diverse mechanisms of action, although only docetaxel alone, or docetaxel in combination with estramustine has offered an established survival benefit in CRPC thus far. Given that cytotoxic drugs have such a narrow therapeutic window (i.e., maximum efficacy and minimum toxicity) within the population suffering from advanced prostate cancer, interindividual variation as it applies to both PK and clinical outcome must be better explored to identify optimal dosing and individuals who are more likely to benefit from treatment with these agents. It is hoped that the information gleaned from such studies will be utilized to improve therapy with cytotoxic agents and eventually lead to the design of superior therapeutic options.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_15.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_15">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1056/NEJMoa041318</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351: 1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_15">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1056/NEJMoa040720</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_15">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Kraus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Samuel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Schmid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Dykes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Waud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Bissery</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>259</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>14578676</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmslCktro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kraus LA, Samuel SK, Schmid SM, Dykes DJ, Waud WR, Bissery MC. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 2003;21: 259–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_15">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>3</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11685722</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotVemsbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0093-7754(01)90148-4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28: 3–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_15">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IE</Initials>
                  <FamilyName>Kuppens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Maanen</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rosing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Schellens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Beijnen</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry</ArticleTitle>
                <JournalTitle>Biomed Chromatogr</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>355</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>15586372</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmsVKmtLw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/bmc.457</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kuppens IE, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005;19: 355–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_15">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Parise</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ramanathan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Zamboni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Egorin</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma</ArticleTitle>
                <JournalTitle>J Chromatogr B Analyt Technol Biomed Life Sci</JournalTitle>
                <VolumeID>783</VolumeID>
                <FirstPage>231</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12450543</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXosFyhsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783: 231–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_15">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LZ</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Goh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Grigg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YM</Initials>
                  <FamilyName>Khoo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma</ArticleTitle>
                <JournalTitle>Rapid Commun Mass Spectrom</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>1548</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>12845579</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsFGmuro%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/rcm.1091</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003;17: 1548–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_15">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Mortier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Lambert</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry</ArticleTitle>
                <JournalTitle>J Chromatogr B Analyt Technol Biomed Life Sci</JournalTitle>
                <VolumeID>1108</VolumeID>
                <FirstPage>195</FirstPage>
                <LastPage>201</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xhslyls7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mortier KA, Lambert WE. Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;1108: 195–201.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_15">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Brahmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry</ArticleTitle>
                <JournalTitle>J Chromatogr B Analyt Technol Biomed Life Sci</JournalTitle>
                <VolumeID>773</VolumeID>
                <FirstPage>183</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>12031845</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xlt1SiurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773: 183–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_15">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Loos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JG</Initials>
                  <FamilyName>Boonstra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>74</VolumeID>
                <FirstPage>364</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>14534523</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXnvVyksrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0009-9236(03)00222-4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74: 364–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_15">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Tije</FamilyName>
                  <Particle>ten</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Relationship of systemic exposure to unbound docetaxel and neutropenia</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>77</VolumeID>
                <FirstPage>43</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>15637530</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXks1Wl</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.clpt.2004.09.005</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77: 43–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_15">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Minami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kawada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sasaki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>235</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>16542221</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xjs1Omu70%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1349-7006.2006.00166.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Minami H, Kawada K, Sasaki Y, et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 2006;97: 235–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_15">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Guentert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Oie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Paalzow</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1987</Year>
                <ArticleTitle Language="En">Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs</ArticleTitle>
                <JournalTitle>Br J Clin Pharmacol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>569</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>3593626</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXkvV2hs7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1365-2125.1987.tb03093.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Guentert TW, Oie S, Paalzow L, et al. Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs. Br J Clin Pharmacol 1987;23: 569–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_15">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Reynolds</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">The role of micelles in protein–detergent interactions</ArticleTitle>
                <JournalTitle>Methods Enzymol</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>58</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>481236</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1MXlvVOqu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reynolds JA. The role of micelles in protein–detergent interactions. Methods Enzymol 1979;61: 58–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_15">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Petitpas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Grune</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Bhattacharya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Curry</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids</ArticleTitle>
                <JournalTitle>J Mol Biol</JournalTitle>
                <VolumeID>314</VolumeID>
                <FirstPage>955</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>11743713</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXptVOls7o%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1006/jmbi.2000.5208</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Petitpas I, Grune T, Bhattacharya AA, Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 2001;314: 955–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_15">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Martinet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Korzekwa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Krausz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>Gonzalez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Gelboin</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver</ArticleTitle>
                <JournalTitle>Pharmacogenetics</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>391</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="PID">
                  <Handle>9825831</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnsFWjsro%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/00008571-199810000-00004</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998;8: 391–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_15">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Herwaarden</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Wagenaar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Kruijssen</FamilyName>
                  <Particle>van der</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>117</VolumeID>
                <FirstPage>3583</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>17975676</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1172/JCI33435</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117: 3583–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_15">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Cusatis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Pharmacogenetic pathway analysis of docetaxel elimination</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>155</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>18509327</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/clpt.2008.95</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Baker S, Verweij J, Cusatis G, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2008;85(2): 155–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_15">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Tran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Jullien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Alexandre</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>570</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>16765145</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xltl2msrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.clpt.2006.02.003</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79: 570–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_15">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Bardelmeijer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ouwehand</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Buckle</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>6158</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>12414642</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosF2ms7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62: 6158–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_15">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MT</Initials>
                  <FamilyName>Huisman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Chhatta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Tellingen</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Beijnen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Schinkel</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>116</VolumeID>
                <FirstPage>824</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15849751</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXosVaqur8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/ijc.21013</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116: 824–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_15">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Acharya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Desai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel</ArticleTitle>
                <JournalTitle>Cancer Biol Ther</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>815</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16210916</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvVSnsLs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4161/cbt.4.8.1867</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4: 815–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_15">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Zuylen</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nooter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Brouwer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Stoter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>2598</FirstPage>
                <LastPage>603</LastPage>
                <Occurrence Type="PID">
                  <Handle>10914699</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6: 2598–603.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_15">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Cordon-Cardo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>O'Brien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Casals</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>695</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>2563168</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXovVWnsw%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.86.2.695</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86: 695–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_15">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Saito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZJ</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ohtsubo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs</ArticleTitle>
                <JournalTitle>Acta Otolaryngol</JournalTitle>
                <VolumeID>121</VolumeID>
                <FirstPage>735</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>11678173</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFyksbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saito T, Zhang ZJ, Ohtsubo T, et al. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol 2001;121: 735–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_15">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Saito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZJ</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shibamori</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites</ArticleTitle>
                <JournalTitle>Neurosci Lett</JournalTitle>
                <VolumeID>232</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>9292887</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmtVKru7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saito T, Zhang ZJ, Shibamori Y, et al. P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites. Neurosci Lett 1997;232: 41–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_15">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Drach</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Drach</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>80</VolumeID>
                <FirstPage>2729</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>1360266</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2FotFOksA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80: 2729–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_15">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Fruehauf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Wermann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EC</Initials>
                  <FamilyName>Buss</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer</ArticleTitle>
                <JournalTitle>Recent Results Cancer Res</JournalTitle>
                <VolumeID>144</VolumeID>
                <FirstPage>93</FirstPage>
                <LastPage>115</LastPage>
                <Occurrence Type="PID">
                  <Handle>9304712</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXktFyis7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fruehauf S, Wermann K, Buss EC, et al. Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer. Recent Results Cancer Res 1998;144: 93–115.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_15">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Gottesman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fojo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Bates</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Multidrug resistance in cancer: role of ATP-dependent transporters</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>48</FirstPage>
                <LastPage>58</LastPage>
                <Occurrence Type="PID">
                  <Handle>11902585</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhvF2jtL8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/nrc706</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 48–58.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_15">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ieiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Takane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Otsubo</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The MDR1 (ABCB1) gene polymorphism and its clinical implications</ArticleTitle>
                <JournalTitle>Clin Pharmacokinet</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>553</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>15217301</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmvVCksL4%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2165/00003088-200443090-00001</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43: 553–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_15">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Burk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Koch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Raucy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <FirstPage>38379</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>15252010</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXnt1Oqt7s%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1074/jbc.M404949200</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004;279: 38379–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_15">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Lehmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>McKee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Willson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Kliewer</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>102</VolumeID>
                <FirstPage>1016</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>9727070</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlvVCqtLY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1172/JCI3703</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102: 1016–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_15">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Danesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>19</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>18187806</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmsVygsg%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1535-7163.MCT-07-0557</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sissung TM, Danesi R, Price DK, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008;7: 19–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_15">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention</ArticleTitle>
                <JournalTitle>Mol Cancer Res</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>135</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>16547151</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XisVaqu78%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1541-7786.MCR-05-0101</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006;4: 135–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_15">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Clinical pharmacokinetics of docetaxel : recent developments</ArticleTitle>
                <JournalTitle>Clin Pharmacokinet</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>235</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>16509758</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjsFOksbw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2165/00003088-200645030-00002</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet 2006;45: 235–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_15">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kloft</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wallin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Henningsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Chatelut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MO</Initials>
                  <FamilyName>Karlsson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>5481</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>17000683</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XpvFShsbg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-06-0815</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006;12: 5481–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_15">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rudek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Garrett-Mayer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>1170</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>15110880</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjtl2nt70%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.ejca.2003.12.026</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40: 1170–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_15">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bruno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Olivares</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Berille</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>1077</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>12631610</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhvFKitLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003;9: 1077–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_15">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bruno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Hille</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Riva</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>187</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>9440742</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsVejtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16: 187–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_15">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Baum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Deeken</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>4543</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18628469</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXosFGitLc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-07-4230</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sissung TM, Baum CE, Deeken J, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008;14: 4543–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_15">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Veyrat-Follet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bruno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Olivares</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Chaikin</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>677</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>11180028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXht1Sjsbg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1067/mcp.2000.111948</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68: 677–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_15">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Strother</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Sweeney</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Lessons learned from development of docetaxel</ArticleTitle>
                <JournalTitle>Expert Opin Drug Metab Toxicol</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>1007</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>18624687</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXos1Chtbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1517/17425255.4.7.1007</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Strother RM, Sweeney C. Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol 2008;4: 1007–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_15">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Clarke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LP</Initials>
                  <FamilyName>Rivory</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Clinical pharmacokinetics of docetaxel</ArticleTitle>
                <JournalTitle>Clin Pharmacokinet</JournalTitle>
                <VolumeID>36</VolumeID>
                <FirstPage>99</FirstPage>
                <LastPage>114</LastPage>
                <Occurrence Type="PID">
                  <Handle>10092957</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitFCntL0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2165/00003088-199936020-00002</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36: 99–114.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_15">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Hooker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Tije</FamilyName>
                  <Particle>Ten</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>111</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18183036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnt1KqsLo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.clpt.6100476</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hooker AC, Ten Tije AJ, Carducci MA, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther 2008;84: 111–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_15">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Urien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Barre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Morin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Paccaly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Montay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Tillement</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>147</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>8913835</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XntFClsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996;14: 147–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_15">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Puisset</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Chatelut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>305</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17124593</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltFSkt7k%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-006-0385-4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Puisset F, Chatelut E, Sparreboom A, et al. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol 2007;60: 305–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_15">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VL</Initials>
                  <FamilyName>Marchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>155</VolumeID>
                <FirstPage>1985</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>10595928</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0002-9440(10)65517-4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155: 1985–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_15">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KC</Initials>
                  <FamilyName>Torkko</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>171</VolumeID>
                <FirstPage>S30</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>14713750</Handle>
                </Occurrence>
                <BibComments>discussion S5</BibComments>
              </BibArticle>
              <BibUnstructured>Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 2004;171: S30–4; discussion S5.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_15">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kuvibidila</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Rayford</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer</ArticleTitle>
                <JournalTitle>J Lab Clin Med</JournalTitle>
                <VolumeID>147</VolumeID>
                <FirstPage>174</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>16581345</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtFant70%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.lab.2005.11.012</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kuvibidila S, Rayford W. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. J Lab Clin Med 2006;147: 174–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_15">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Cooper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Houghton</FamilyName>
                </BibAuthorName>
                <Year>1977</Year>
                <ArticleTitle Language="En">Acute phase reactant proteins in prostatic cancer</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>411</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>73395</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE1c%2FmtFGhtA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1464-410X.1977.tb04168.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ward AM, Cooper EH, Houghton AL. Acute phase reactant proteins in prostatic cancer. Br J Urol 1977;49: 411–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_15">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Puisset</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Alexandre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Treluyer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Clinical pharmacodynamic factors in docetaxel toxicity</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>290</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>17595656</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXotlSgtrw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.bjc.6603872</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Puisset F, Alexandre J, Treluyer JM, et al. Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 2007;97: 290–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_15">
              <CitationNumber>52</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <BookTitle>Effect of androgen-ablation and hormonal cycling on docetaxel clearance in patients with metastatic prostate cancer</BookTitle>
                <BibComments>Proc ASCO (abst 4608)</BibComments>
              </BibBook>
              <BibUnstructured>Baker SD, Scher HI, Li J, et al. Effect of androgen-ablation and hormonal cycling on docetaxel clearance in patients with metastatic prostate cancer. Proc ASCO (abst 4608) 2005.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_15">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Rathkopf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>2959</FirstPage>
                <LastPage>65</LastPage>
                <Occurrence Type="PID">
                  <Handle>18565882</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXoslOqs7Y%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2007.15.1928</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Rathkopf D, Carducci MA, Morris MJ, et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 2008;26: 2959–65.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_15">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VJ</Initials>
                  <FamilyName>Sinibaldi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Elza-Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>29</VolumeID>
                <FirstPage>395</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16891869</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XptVKitr8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/01.coc.0000225411.95479.b4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sinibaldi VJ, Elza-Brown K, Schmidt J, et al. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 2006;29: 395–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_15">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hochegger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Lhotta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Czejka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Hilbe</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer</ArticleTitle>
                <JournalTitle>Nephrol Dial Transplant</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>289</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>16935890</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXivFCkug%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1093/ndt/gfl498</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hochegger K, Lhotta K, Mayer G, Czejka M, Hilbe W. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant 2007;22: 289–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_15">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Tije</FamilyName>
                  <Particle>ten</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>1070</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15718305</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2005.03.082</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23: 1070–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_15">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hurria</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MT</Initials>
                  <FamilyName>Fleming</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacokinetics and toxicity of weekly docetaxel in older patients</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>6100</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>17062686</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFWhsbnK</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-06-0200</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12: 6100–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_15">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bruno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Vivier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Veyrat-Follet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Montay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>163</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11392450</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktF2qurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19: 163–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_15">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kaira</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tsuchiya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sunaga</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>30</VolumeID>
                <FirstPage>51</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>17278895</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/01.coc.0000242292.17728.46</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kaira K, Tsuchiya S, Sunaga N, et al. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol 2007;30: 51–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_15">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>LeCaer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Barlesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Robinet</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study</ArticleTitle>
                <JournalTitle>Lung Cancer</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>72</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17391803</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.lungcan.2007.02.012</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>LeCaer H, Barlesi F, Robinet G, et al. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. Lung Cancer 2007;57: 72–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_15">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Takigawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Segawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kishino</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>230</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15127232</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmt1Kks7Y%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-004-0826-x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Takigawa N, Segawa Y, Kishino D, et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004;54: 230–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_15">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Bosch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Huitema</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VD</Initials>
                  <FamilyName>Doodeman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>5786</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>17020985</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVartbjM</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-05-2649</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006;12: 5786–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_15">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FK</Initials>
                  <FamilyName>Engels</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Loos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Mathot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Schaik</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Influence of ketoconazole on the fecal and urinary disposition of docetaxel</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>569</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>17256132</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnvFKntro%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-006-0412-5</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother Pharmacol 2007;60: 569–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_15">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Goh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LZ</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>3683</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>12202670</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XntVynsrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2002.01.025</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20: 3683–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_15">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Hahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Marsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Fisher</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>6094</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17062685</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFWhsbnJ</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-06-1188</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hahn NM, Marsh S, Fisher W, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006;12: 6094–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_15">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Hor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CI</Initials>
                  <FamilyName>Wong</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients</ArticleTitle>
                <JournalTitle>Pharmacogenomics J</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>139</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>17876342</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXjtlKjur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008;8: 139–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_15">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kiyotani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Mushiroda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kubo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zembutsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sugiyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Nakamura</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>967</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>18294295</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslCrtrs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1349-7006.2008.00765.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008;99: 967–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_15">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LD</Initials>
                  <FamilyName>Lewis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Rosner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>3302</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>17545536</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmtVaju7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-06-2345</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lewis LD, Miller AA, Rosner GL, et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13: 3302–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_15">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Daly</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Significance of the minor cytochrome P450 3A isoforms</ArticleTitle>
                <JournalTitle>Clin Pharmacokinet</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>13</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>16430309</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xis1ejsbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2165/00003088-200645010-00002</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45: 13–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_15">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>3312</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519758</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmslygsL8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-07-4118</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14: 3312–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_15">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>102</VolumeID>
                <FirstPage>617</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>18537956</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFSlurjE</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1464-410X.2008.07629.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008;102: 617–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_15">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Bessho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Oguri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Achiwa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>192</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16542215</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xjs1Omurk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1349-7006.2006.00164.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bessho Y, Oguri T, Achiwa H, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006;97: 192–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_15">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mizuarai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Aozasa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kotani</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>109</VolumeID>
                <FirstPage>238</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>14750175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhvVCksrs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/ijc.11669</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004;109: 238–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_15">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Tham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NH</Initials>
                  <FamilyName>Holford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Hor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>7126</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>18056193</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlyitL3J</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tham LS, Holford NH, Hor SY, et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 2007;13: 7126–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_15">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rochat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Morsman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GI</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</ArticleTitle>
                <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                <VolumeID>296</VolumeID>
                <FirstPage>537</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>11160641</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXoslejtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001;296: 537–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_15">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Bournique</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lemarie</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme</ArticleTitle>
                <JournalTitle>Drug Metab Dispos</JournalTitle>
                <VolumeID>30</VolumeID>
                <FirstPage>1149</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>12386117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XotFyktbc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1124/dmd.30.11.1149</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bournique B, Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 2002;30: 1149–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_15">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Carnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FM</Initials>
                  <FamilyName>Daley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue</ArticleTitle>
                <JournalTitle>Int J Radiat Oncol Biol Phys</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>500</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>14751521</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXnvVKltQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.ijrobp.2003.09.064</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Carnell DM, Smith RE, Daley FM, et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys 2004;58: 500–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_15">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Brandi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Rosa</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Danesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GC</Initials>
                  <FamilyName>Montini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Biasco</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>54</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>938</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>18657896</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtlGgu7%2FL</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.eururo.2008.07.029</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Brandi G, de Rosa F, Danesi R, Montini GC, Biasco G. Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms? Eur Urol 2008;54(4):938–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_15">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1047</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>17437439</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmvVaqsLk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1464-410X.2007.06763.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Figg WD, Li H, Sissung T, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007;99: 1047–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_15">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Markushin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Gaikwad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Potential biomarker for early risk assessment of prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>1565</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>16894534</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFWks73N</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/pros.20484</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Markushin Y, Gaikwad N, Zhang H, et al. Potential biomarker for early risk assessment of prostate cancer. Prostate 2006;66: 1565–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_15">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Tewey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Rowe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BD</Initials>
                  <FamilyName>Halligan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LF</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>226</VolumeID>
                <FirstPage>466</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>6093249</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXmt1ahs7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1126/science.6093249</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226: 466–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_15">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NR</Initials>
                  <FamilyName>Bachur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Hickey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Malkas</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Helicase inhibition by anthracycline anticancer agents</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>993</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1614415</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XlvVCnsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992;41: 993–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_15">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Myers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WP</Initials>
                  <FamilyName>McGuire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Liss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ifrim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Grotzinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Young</FamilyName>
                </BibAuthorName>
                <Year>1977</Year>
                <ArticleTitle Language="En">Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>197</VolumeID>
                <FirstPage>165</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>877547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE2sXltFWlsLs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1126/science.877547</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197: 165–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_15">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Hande</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Clinical applications of anticancer drugs targeted to topoisomerase II</ArticleTitle>
                <JournalTitle>Biochim Biophys Acta</JournalTitle>
                <VolumeID>1400</VolumeID>
                <FirstPage>173</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>9748560</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmtFWis74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0167-4781(98)00134-1</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998;1400: 173–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_15">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Vibet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Maheo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Dubois</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Bougnoux</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Chourpa</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines</ArticleTitle>
                <JournalTitle>Drug Metab Dispos</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>822</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17296624</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsVWmur0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1124/dmd.106.013474</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Vibet S, Maheo K, Gore J, Dubois P, Bougnoux P, Chourpa I. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos 2007;35: 822–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_15">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Levine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gherson</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues</ArticleTitle>
                <JournalTitle>Int J Immunopharmacol</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>999</FirstPage>
                <LastPage>1007</LastPage>
                <Occurrence Type="PID">
                  <Handle>3492454</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXnvVeluw%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/0192-0561(86)90102-5</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int J Immunopharmacol 1986;8: 999–1007.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_15">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Dakhil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Modiano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gregurich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Asmar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <FirstPage>2439</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441935</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovVehsbw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0022-5347(05)64163-8</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168: 2439–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_15">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Conaway</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>2506</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561316</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17: 2506–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_15">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stockler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1756</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8656243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslOrsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14: 1756–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_15">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schleyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kamischke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Kaufmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Unterhalt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Hiddemann</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites</ArticleTitle>
                <JournalTitle>Leukemia</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>435</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>8127148</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7ntlSqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schleyer E, Kamischke A, Kaufmann CC, Unterhalt M, Hiddemann W. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 1994;8: 435–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_15">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Launay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Iliadis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Richard</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Population pharmacokinetics of mitoxantrone performed by a NONMEM method</ArticleTitle>
                <JournalTitle>J Pharm Sci</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>877</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>2600798</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXmt1Cktbc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/jps.2600781020</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Launay MC, Iliadis A, Richard B. Population pharmacokinetics of mitoxantrone performed by a NONMEM method. J Pharm Sci 1989;78: 877–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_15">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schurr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Raymond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Gros</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>2729</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>2565763</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXktVSgtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schurr E, Raymond M, Bell JC, Gros P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 1989;49: 2729–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_15">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Morrow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Smitherman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Diah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schneider</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Townsend</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>273</VolumeID>
                <FirstPage>20114</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>9685354</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlsVWgsbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem 1998;273: 20114–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_15">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schneider</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Horton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakagawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Cowan</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>152</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>7903202</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXht1Churw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994;54: 152–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_15">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Morrow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Peklak-Scott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Bishwokarma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Kute</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Smitherman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Townsend</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>69</VolumeID>
                <FirstPage>1499</FirstPage>
                <LastPage>505</LastPage>
                <Occurrence Type="PID">
                  <Handle>16434618</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlKnu74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1124/mol.105.017988</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 2006;69: 1499–505.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_15">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Hooijberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Broxterman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kool</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>2532</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10363967</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1ymsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59: 2532–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_15">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Doyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LV</Initials>
                  <FamilyName>Abruzzo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">A multidrug resistance transporter from human MCF-7 breast cancer cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>15665</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>9861027</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhvFeitQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.95.26.15665</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95: 15665–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_15">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Miyake</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Mickley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Litman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>8</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>9892175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsFKqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59: 8–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_15">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Pan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WF</Initials>
                  <FamilyName>Elmquist</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Mitoxantrone permeability in MDCKII cells is influenced by active influx transport</ArticleTitle>
                <JournalTitle>Mol Pharm</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>475</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17388607</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjsVOrsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pan G, Elmquist WF. Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol Pharm 2007;4: 475–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_15">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bhangal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Roylance</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Shah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Waxman</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Expression of the multidrug resistance gene in human prostate cancer</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>118</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>10765019</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S1078-1439(99)00055-1</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000;5: 118–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_15">
              <CitationNumber>101</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Huss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Gray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>6640</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>16061644</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmvFSlt7w%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/0008-5472.CAN-04-2548</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005;65: 6640–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_15">
              <CitationNumber>102</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MN</Initials>
                  <FamilyName>Fedoruk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Gimenez-Bonafe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Guns</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LD</Initials>
                  <FamilyName>Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>77</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>14991868</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsVWltLo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/pros.10354</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004;59: 77–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_15">
              <CitationNumber>103</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Allen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Schinkel</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2)</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>427</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>12477055</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xjt1yqs7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002;1: 427–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_15">
              <CitationNumber>104</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Hirschmann-Jax</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Foster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Wulf</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">A distinct "side population" of cells with high drug efflux capacity in human tumor cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>14228</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>15381773</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXosVyltr8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.0400067101</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101: 14228–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_15">
              <CitationNumber>105</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Seiter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Damon</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia</ArticleTitle>
                <JournalTitle>Leukemia</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>485</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9096687</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnsl2itg%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.leu.2400623</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997;11: 485–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_15">
              <CitationNumber>106</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Imai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kage</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>611</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12479221</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFSlsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_15">
              <CitationNumber>107</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kobayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ieiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hirota</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta</ArticleTitle>
                <JournalTitle>Drug Metab Dispos</JournalTitle>
                <VolumeID>33</VolumeID>
                <FirstPage>94</FirstPage>
                <LastPage>101</LastPage>
                <Occurrence Type="PID">
                  <Handle>15475413</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltlegtA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1124/dmd.104.001628</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kobayashi D, Ieiri I, Hirota T, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005;33: 94–101.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_15">
              <CitationNumber>108</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kolwankar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Glover</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Ware</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TS</Initials>
                  <FamilyName>Tracy</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Expression and function of ABCB1 and ABCG2 in human placental tissue</ArticleTitle>
                <JournalTitle>Drug Metab Dispos</JournalTitle>
                <VolumeID>33</VolumeID>
                <FirstPage>524</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15640379</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtFCjsr0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1124/dmd.104.002261</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kolwankar D, Glover DD, Ware JA, Tracy TS. Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos 2005;33: 524–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_15">
              <CitationNumber>109</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kondo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Itoda</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Functional analysis of SNPs variants of BCRP/ABCG2</ArticleTitle>
                <JournalTitle>Pharm Res</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>1895</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="PID">
                  <Handle>15553238</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXos1Wqtrk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1023/B:PHAM.0000045245.21637.d4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kondo C, Suzuki H, Itoda M, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004;21: 1895–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_15">
              <CitationNumber>110</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Gelderblom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Marsh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Diflomotecan pharmacokinetics in relation to ABCG2 421C&gt;A genotype</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>38</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>15229462</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlsVaqtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C&gt;A genotype. Clin Pharmacol Ther 2004;76: 38–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR111_15">
              <CitationNumber>111</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Morisaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Robey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ozvegy-Laczka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Single nucleotide polymorphisms modify the transporter activity of ABCG2</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>161</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>15838659</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXksl2hu7Y%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-004-0931-x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Morisaki K, Robey RW, Ozvegy-Laczka C, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56: 161–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR112_15">
              <CitationNumber>112</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Tamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Wakabayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Onishi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>231</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17297656</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsFKjtbk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1349-7006.2006.00371.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Tamura A, Wakabayashi K, Onishi Y, et al. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 2007;98: 231–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR113_15">
              <CitationNumber>113</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sugimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tsukahara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ishikawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Mitsuhashi</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>96</VolumeID>
                <FirstPage>457</FirstPage>
                <LastPage>65</LastPage>
                <Occurrence Type="PID">
                  <Handle>16108826</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVWisLjL</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1349-7006.2005.00081.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005;96: 457–65.</BibUnstructured>
            </Citation>
            <Citation ID="CR114_15">
              <CitationNumber>114</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Honjo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Hrycyna</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>QW</Initials>
                  <FamilyName>Yan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>6635</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11559526</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXntFaisr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61: 6635–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR115_15">
              <CitationNumber>115</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Polgar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Deeken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Ediriwickrema</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant</ArticleTitle>
                <JournalTitle>Mol Cell Biochem</JournalTitle>
                <VolumeID>322</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>63</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>19002564</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Polgar O, Deeken JF, Ediriwickrema LS, et al. The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. Mol Cell Biochem 2008;322(1–2): 63–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR116_15">
              <CitationNumber>116</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Gardner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Pharmacogenetics of membrane transporters: a review of current approaches</ArticleTitle>
                <JournalTitle>Methods Mol Biol</JournalTitle>
                <VolumeID>448</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>18370230</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXksl2hsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sissung TM, Gardner ER, Gao R, Figg WD. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol 2008;448: 41–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR117_15">
              <CitationNumber>117</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Benderra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Faussat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Sayada</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>7896</FirstPage>
                <LastPage>902</LastPage>
                <Occurrence Type="PID">
                  <Handle>15585622</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVCrs73O</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-04-0795</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10: 7896–902.</BibUnstructured>
            </Citation>
            <Citation ID="CR118_15">
              <CitationNumber>118</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Sandberg</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Metabolic aspects and actions unique to Estracyt</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>3</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>6364364</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXhtlWrtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sandberg AA. Metabolic aspects and actions unique to Estracyt. Semin Oncol 1983;10: 3–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR119_15">
              <CitationNumber>119</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Muechler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kohler</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">Interaction of the cytotoxic agent estramustine phosphate (Estracyt) with the estrogen receptor of the human uterus</ArticleTitle>
                <JournalTitle>Gynecol Oncol</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>330</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>510999</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXhtVCltrk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/0090-8258(79)90042-8</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Muechler EK, Kohler D. Interaction of the cytotoxic agent estramustine phosphate (Estracyt) with the estrogen receptor of the human uterus. Gynecol Oncol 1979;8: 330–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR120_15">
              <CitationNumber>120</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Ho</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>491</FirstPage>
                <LastPage>503</LastPage>
                <Occurrence Type="PID">
                  <Handle>14755680</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsVWjs74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/jcb.10759</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91: 491–503.</BibUnstructured>
            </Citation>
            <Citation ID="CR121_15">
              <CitationNumber>121</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Bergenheim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Henriksson</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Pharmacokinetics and pharmacodynamics of estramustine phosphate</ArticleTitle>
                <JournalTitle>Clin Pharmacokinet</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>163</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>9515186</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhsFaisro%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2165/00003088-199834020-00004</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet 1998;34: 163–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR122_15">
              <CitationNumber>122</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Hartley-Asp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kruse</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Nuclear protein matrix as a target for estramustine-induced cell death</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>387</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>3786258</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXksVamsQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/pros.2990090408</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986;9: 387–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR123_15">
              <CitationNumber>123</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Lehr</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>149</VolumeID>
                <FirstPage>1622</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>8501820</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3nsVOksA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/1097-0142(19950401)75:7+%3C1920::AID-CNCR2820751627%3E3.0.CO;2-Y</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993;149: 1622–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR124_15">
              <CitationNumber>124</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Tritsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Shukla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mittelman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Year>1974</Year>
                <ArticleTitle Language="En">Estracyt (NSC 89199) as a substrate for phosphatases in human serum</ArticleTitle>
                <JournalTitle>Invest Urol</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>38</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>4366126</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE2c3ms1Cmtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tritsch GL, Shukla SK, Mittelman A, Murphy GP. Estracyt (NSC 89199) as a substrate for phosphatases in human serum. Invest Urol 1974;12: 38–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR125_15">
              <CitationNumber>125</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Calabro</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>196</FirstPage>
                <LastPage>202</LastPage>
                <Occurrence Type="PID">
                  <Handle>9052470</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhsFeqtrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1046/j.1464-410X.1997.06310.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79: 196–202.</BibUnstructured>
            </Citation>
            <Citation ID="CR126_15">
              <CitationNumber>126</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Forsgren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Bjork</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Carlstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Gustafsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pousette</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Hogberg</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17 beta</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>3149</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>290993</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1MXltFyqtLs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.76.7.3149</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Forsgren B, Bjork P, Carlstrom K, Gustafsson JA, Pousette A, Hogberg B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17 beta. Proc Natl Acad Sci U S A 1979;76: 3149–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR127_15">
              <CitationNumber>127</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PO</Initials>
                  <FamilyName>Gunnarsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Forshell</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Clinical pharmacokinetics of estramustine phosphate</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>22</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>6375076</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3isFClug%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0090-4295(84)80093-X</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gunnarsson PO, Forshell GP. Clinical pharmacokinetics of estramustine phosphate. Urology 1984;23: 22–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR128_15">
              <CitationNumber>128</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Mamun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>752</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16126332</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1CnsrbK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Suzuki M, Mamun MR, Hara K, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol 2005;48: 752–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR129_15">
              <CitationNumber>129</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zahid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Saeed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Cavalieri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EG</Initials>
                  <FamilyName>Rogan</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>105</VolumeID>
                <FirstPage>150</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17582757</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXovFyitbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu F, Zahid M, Saeed M, Cavalieri EL, Rogan EG. Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 2007;105: 150–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR130_15">
              <CitationNumber>130</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zahid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Saeed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Gaikwad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Rogan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Cavalieri</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation</ArticleTitle>
                <JournalTitle>Free Radic Biol Med</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>1534</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>17964424</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aktr7N</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zahid M, Saeed M, Lu F, Gaikwad N, Rogan E, Cavalieri E. Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation. Free Radic Biol Med 2007;43: 1534–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR131_15">
              <CitationNumber>131</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Muto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients</ArticleTitle>
                <JournalTitle>Int J Urol</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>166</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>15733111</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1442-2042.2005.01004.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Suzuki M, Muto S, Hara K, et al. Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients. Int J Urol 2005;12: 166–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR132_15">
              <CitationNumber>132</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Boulikas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Vougiouka</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Cisplatin and platinum drugs at the molecular level. (Review)</ArticleTitle>
                <JournalTitle>Oncol Rep</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>1663</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>14534679</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXptlCktLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003;10: 1663–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR133_15">
              <CitationNumber>133</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Mellish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CF</Initials>
                  <FamilyName>Barnard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Murrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LR</Initials>
                  <FamilyName>Kelland</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>717</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>7558420</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXpslWhu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995;62: 717–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR134_15">
              <CitationNumber>134</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CF</Initials>
                  <FamilyName>O'Neill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Koberle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Masters</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LR</Initials>
                  <FamilyName>Kelland</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>1294</FirstPage>
                <LastPage>303</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604725</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj/bjc/6694381</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>O’Neill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81: 1294–303.</BibUnstructured>
            </Citation>
            <Citation ID="CR135_15">
              <CitationNumber>135</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ZH</Initials>
                  <FamilyName>Siddik</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Cisplatin: mode of cytotoxic action and molecular basis of resistance</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>7265</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>14576837</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXotlajtbY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.onc.1206933</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22: 7265–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR136_15">
              <CitationNumber>136</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Benedetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Malina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kasparkova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Brabec</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Natile</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Chiral discrimination in platinum anticancer drugs</ArticleTitle>
                <JournalTitle>Environ Health Perspect</JournalTitle>
                <VolumeID>110</VolumeID>
                <IssueID>Suppl 5</IssueID>
                <FirstPage>779</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>12426131</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovFKhsb4%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1289/ehp.02110s5779</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Benedetti M, Malina J, Kasparkova J, Brabec V, Natile G. Chiral discrimination in platinum anticancer drugs. Environ Health Perspect 2002;110 Suppl 5: 779–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR137_15">
              <CitationNumber>137</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Fink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Nebel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Aebi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">The role of DNA mismatch repair in platinum drug resistance</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>4881</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8895738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmsFygsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56: 4881–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR138_15">
              <CitationNumber>138</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Silverman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Bu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Lippard</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2+ bound to a dodecamer DNA duplex</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <FirstPage>49743</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12377787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XpsFakt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Silverman AP, Bu W, Cohen SM, Lippard SJ. 2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2+ bound to a dodecamer DNA duplex. J Biol Chem 2002;277: 49743–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR139_15">
              <CitationNumber>139</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Reardon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaisman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Chaney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sancar</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>3968</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>10463593</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXlsVOltLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59: 3968–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR140_15">
              <CitationNumber>140</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FI</Initials>
                  <FamilyName>Raynaud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mistry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Donaghue</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Biotransformation of the platinum drug JM216 following oral administration to cancer patients</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>38</VolumeID>
                <FirstPage>155</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>8616906</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslClsL0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s002800050464</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Raynaud FI, Mistry P, Donaghue A, et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996;38: 155–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR141_15">
              <CitationNumber>141</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Carr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Tingle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McKeage</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Rapid biotransformation of satraplatin by human red blood cells in vitro</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>9</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>12111106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XkvVagu78%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-002-0462-2</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Carr JL, Tingle MD, McKeage MJ. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 2002;50: 9–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR142_15">
              <CitationNumber>142</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Kelland</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>1009</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>17594186</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmvVOmt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16: 1009–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR143_15">
              <CitationNumber>143</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Samimi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Howell</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>781</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16170571</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlWnsrw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-005-0121-5</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 2006;57: 781–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR144_15">
              <CitationNumber>144</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LR</Initials>
                  <FamilyName>Kelland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Abel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McKeage</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>2581</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8388318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXltVyms7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993;53: 2581–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR145_15">
              <CitationNumber>145</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Samimi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kishimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Manorek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Breaux</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Howell</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>301</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>16770583</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlCksb%2FM</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-006-0271-0</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol 2007;59: 301–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR146_15">
              <CitationNumber>146</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Wosikowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Lamphere</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Unteregger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Preclinical antitumor activity of the oral platinum analog satraplatin</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>589</FirstPage>
                <LastPage>600</LastPage>
                <Occurrence Type="PID">
                  <Handle>17541592</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnvFKnt74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s00280-007-0502-z</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60: 589–600.</BibUnstructured>
            </Citation>
            <Citation ID="CR147_15">
              <CitationNumber>147</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Yagoda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>71</VolumeID>
                <FirstPage>1098</FirstPage>
                <LastPage>109</LastPage>
                <Occurrence Type="PID">
                  <Handle>7679039</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s7ltlOgsg%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/1097-0142(19930201)71:3+%3C1098::AID-CNCR2820711432%3E3.0.CO;2-G</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71: 1098–109.</BibUnstructured>
            </Citation>
            <Citation ID="CR148_15">
              <CitationNumber>148</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Lamphere</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Casazza</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Synergistic antitumor activity of the combination of satraplatin (S) and docetaxel (D) in H460 human non-small cell lung carcinoma (NSCLC) xenografted in nude mice</ArticleTitle>
                <JournalTitle>Proc Am Assoc Cancer Res</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>563</FirstPage>
              </BibArticle>
              <BibUnstructured>Lamphere L, Wang S, Casazza AM. Synergistic antitumor activity of the combination of satraplatin (S) and docetaxel (D) in H460 human non-small cell lung carcinoma (NSCLC) xenografted in nude mice. Proc Am Assoc Cancer Res 2006;47: Abstract no. 563.</BibUnstructured>
            </Citation>
            <Citation ID="CR149_15">
              <CitationNumber>149</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Ando</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Shimizu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nakamura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>1170</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>9820175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXntlSqsL4%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/bjc.1998.649</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ando Y, Shimizu T, Nakamura K, et al. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer 1998;78: 1170–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR150_15">
              <CitationNumber>150</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Sternberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>27</VolumeID>
                <FirstPage>5431</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>19805692</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhsFKkt7vJ</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2008.20.1228</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27: 5431–8.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
